A drug used alone or with trametinib to treat melanoma that cannot be removed by surgery or has spread to other parts of the body. It is used in patients with a mutated (changed) form of a cell protein called BRAF. It is also being studied in the treatment of other types of cancer. Dabrafenib blocks this mutated protein, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor and a type of targeted therapy.
An orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.